Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Assets

GH001

GH Research

Molecule class
mebufotenin, inhaled (same molecule as BPL-003, different route)
Mechanism
Not independently verified.
Phase
Phase 2b complete
Indication
treatment-resistant depression
Sponsor geography
IE
Next catalyst
None recorded.
IP status
Not checked. Recorded as unchecked rather than left blank.

clinicaltrials.govregistryverified 2026-08-25

Registered trials

  • NCT05800860ClinicalTrials.gov

    PHASE2 · Treatment-resistant Depression · COMPLETED · Czechia, Germany, Ireland, Netherlands, Poland, Spain

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05804708ClinicalTrials.gov

    PHASE2 · Postpartum Depression;Postnatal Depression · TERMINATED · Netherlands, United Kingdom

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05839509ClinicalTrials.gov

    PHASE2 · Bipolar II Disorder · TERMINATED · Germany, Netherlands, United Kingdom

    clinicaltrials.govctgov registryverified 2026-08-31

  • 2023-510047-37-00CTIS

    Therapeutic exploratory (Phase II) · Treatment-resistant depression (TRD) · Ended · Czechia, Germany, Ireland, Poland, Spain

    euclinicaltrials.euctis registryverified 2026-08-31

In the briefing

Issues tagged GH, the owner of this asset.